REGENXBIO (RGNX) CMO sells 5,124 shares under 10b5-1 plan

Rhea-AI Filing Summary

REGENXBIO Inc. Chief Medical Officer Steve Pakola reported an open-market sale of 5,124 shares of common stock at $10.35 per share. After this transaction, he directly holds 247,926 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance as part of routine portfolio management.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAKOLA STEVE

(Last) (First) (Middle)

C/O REGENXBIO INC.

9804 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		S(1)		5,124	D	$10.35	247,926	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Remarks:

	/s/ Patrick J. Christmas as attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did REGENXBIO (RGNX) report for Steve Pakola?

REGENXBIO reported that Chief Medical Officer Steve Pakola sold 5,124 shares of common stock. The shares were sold in an open-market transaction at $10.35 per share, under a Rule 10b5-1 trading plan that pre-schedules trades.

How many REGENXBIO (RGNX) shares does Steve Pakola hold after this Form 4?

Following the reported sale, Steve Pakola directly holds 247,926 shares of REGENXBIO common stock. This position is disclosed in the Form 4 as his total direct ownership immediately after the 5,124-share open-market sale on the reported date.

Was the REGENXBIO (RGNX) insider sale by Steve Pakola pre-planned?

Yes. A footnote explains the transaction was effected under a Rule 10b5-1 trading plan. Such plans allow insiders to pre-schedule trades, helping separate normal portfolio management from discretionary market-timed transactions for regulatory and corporate governance purposes.

What price did Steve Pakola receive per share in the REGENXBIO (RGNX) sale?

Steve Pakola sold 5,124 REGENXBIO common shares at an average price of $10.35 each. This price reflects the consideration per share in the open-market transaction reported in the Form 4, which details the insider’s trading activity.

Does the REGENXBIO (RGNX) Form 4 show any option exercises or gifts?

No. The Form 4 discloses a single non-derivative open-market sale of common stock. The transaction summary shows no option exercises, gifts, tax withholding events, or derivative transactions associated with this particular insider filing.